

Eduard Cmunt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/711323/publications.pdf>

Version: 2024-02-01

18
papers

200
citations

1307594

7
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

438
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry. <i>European Journal of Haematology</i> , 2011, 87, 157-168.	2.2	34
2	Incidence of chromosomal anomalies detected with FISH and their clinical correlations in B-chronic lymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2005, 160, 27-34.	1.0	31
3	Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. <i>Neoplasma</i> , 2011, 58, 256-262.	1.6	22
4	Thrombosis in thrombocytopenic myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. <i>European Journal of Haematology</i> , 2016, 96, 98-106.	2.2	21
5	Clonal evolution in chronic lymphocytic leukemia studied by interphase fluorescence in-situ hybridization. <i>Neoplasma</i> , 2009, 56, 455-458.	1.6	21
6	Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group. <i>Blood</i> , 2014, 124, 4670-4670.	1.4	16
7	Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. <i>European Journal of Haematology</i> , 2011, 87, 130-137.	2.2	15
8	First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter. <i>Leukemia Research</i> , 2019, 81, 67-74.	0.8	7
9	Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. <i>Leukemia Research</i> , 2019, 79, 17-21.	0.8	7
10	Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group. <i>Blood</i> , 2010, 116, 2466-2466.	1.4	6
11	Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications. <i>American Journal of Hematology</i> , 2013, 88, 790-797.	4.1	4
12	Lenalidomide treatment in lower risk myelodysplastic syndromes – The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in) <i>Tj ETQq0 0 0 rgBT (Overlock 40 Tf 50 20</i>	1.4	4
13	Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission. <i>Blood</i> , 2021, 138, 3606-3606.	1.4	4
14	Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia. <i>Neoplasma</i> , 2010, 57, 215-221.	1.6	3
15	Evaluation of 5-year imatinib treatment of 458 patients with <sc>CP</sc> CML</sc> in routine clinical practice and prognostic impact of different <sc>BCR</sc> ABL</sc> cutoff levels. <i>Cancer Medicine</i> , 2013, 2, 216-225.	2.8	3
16	Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. <i>Leukemia and Lymphoma</i> , 2013, 54, 2310-2313.	1.3	2
17	P-202 MDS development risk in CLL patients with prolonged cytopenia after fludarabine, cyclophosphamide and rituximab (FCR) rÅ©gime. <i>Leukemia Research</i> , 2013, 37, S114-S115.	0.8	0
18	Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 1790-1790.	1.4	0